Skip to Main content Skip to Navigation
Journal articles

Efficacy of anti-PD1 re-treatment in patients with Hodgkin lymphoma who relapsed after anti-PD1 discontinuation

Abstract : Patients with relapsed/refractory Hodgkin lymphoma (R/R HL) experience high response rates upon anti-PD1 therapy. In these patients, there is limited data about the optimal duration of treatment and the risk of relapse after anti-PD1 discontinuation. We have previously reported the outcome of 11 patients with R/R HL who discontinued anti-PD1 therapy after achieving a complete response (CR) upon nivolumab1 . These patients experienced favorable outcome as only 2 of them had relapsed after a median follow-up of 21.2 months from discontinuation. Despite the low relapse rate observed in that study, physicians may be worried about the possibility to further rescue these heavily pre-treated patients in case of relapse after anti-PD1 discontinuation. Notably, it is still unknown whether these patients will remain sensitive to a 2nd course of anti-PD1.
Complete list of metadatas

Cited literature [7 references]  Display  Hide  Download

https://hal-univ-rennes1.archives-ouvertes.fr/hal-02485796
Contributor : Laurent Jonchère <>
Submitted on : Wednesday, March 25, 2020 - 10:38:34 AM
Last modification on : Friday, July 3, 2020 - 9:08:51 AM
Long-term archiving on: : Friday, June 26, 2020 - 1:18:39 PM

File

Manson et al-2020-Efficacy of ...
Files produced by the author(s)

Identifiers

Citation

Guillaume Manson, Pauline Brice, Charles Herbaux, Kamal Bouabdallah, Chloé Antier, et al.. Efficacy of anti-PD1 re-treatment in patients with Hodgkin lymphoma who relapsed after anti-PD1 discontinuation. Haematologica, Ferrata Storti Foundation, 2020, pp.haematol.2019.242529. ⟨10.3324/haematol.2019.242529⟩. ⟨hal-02485796⟩

Share

Metrics

Record views

310

Files downloads

172